Contradictory Effects of β1- and α1- Aderenergic Receptor Blockers on Cardio-Ankle Vascular Stiffness Index (CAVI)

Kohji Shirai, Mingling Song, Jun Suzuki, Takumi Kurosu, Tomokazu Oyama, Daiji Nagayama, Yoh Miyashita, Shigeo Yamamura, M TakahashiJournal of Atherosclerosis and Thrombosis 2011 · DOI

Abstract

Assessing arterial stiffness is a critical component of cardiovascular risk prediction. However, the gold-standard metric, Pulse Wave Velocity (PWV), is significantly influenced by blood pressure (BP) at the time of measurement. This study investigates the Cardio-Ankle Vascular Stiffness Index (CAVI), a theoretically BP-independent alternative. By pharmacologically manipulating BP through two distinct mechanisms—reducing cardiac output ($\beta1$-blockade) and inducing vasodilation ($\alpha1$-blockade)—we demonstrate that CAVI remains stable during BP drops caused by cardiac factors but decreases when arterial smooth muscle relaxes. These results confirm that CAVI measures intrinsic arterial properties and functional smooth muscle tone rather than acute mechanical pressure.

Introduction

Arterial stiffness is a major predictor of cardiovascular disease. While Pulse Wave Velocity (PWV) is widely used, its dependence on instantaneous blood pressure creates a diagnostic challenge: it is difficult to distinguish between structural arterial hardening (sclerosis) and temporary tension due to high BP. CAVI was developed to address this by incorporating the stiffness parameter beta, which mathematically adjusts for BP. This study aims to clinically validate the BP-independence of CAVI by comparing it to brachial-ankle PWV (baPWV) under different pharmacological conditions.

Methods

The study employed a crossover design with 12 healthy male volunteers (mean age 47). Subjects were administered two different agents one week apart:

  1. Metoprolol (80 mg): A selective $\beta1$-blocker that lowers BP by reducing heart rate and cardiac contractility without direct vascular effects.
  2. Doxazosin (4 mg): An $\alpha1$-blocker that lowers BP by relaxing arterial smooth muscle cells (vasodilation).

Physiological parameters, including CAVI, baPWV, BP, and heart rate, were monitored hourly for six hours post-administration using the VaSera clinical system. This allowed researchers to isolate whether changes in stiffness metrics were driven by internal pressure changes or changes in the vessel wall itself.

Key Results: Mechanical vs. Functional Response

The pharmacological challenge revealed a stark contrast in how CAVI and baPWV respond to blood pressure reduction.

Figure 1: Time-course changes in CAVI, baPWV, blood pressure, and heart rate after administration of Metoprolol (A) and Doxazosin (B).

As shown in Figure 1, Metoprolol successfully lowered systolic BP (from ~131 to ~118 mmHg) and heart rate. Under these conditions, baPWV decreased significantly, reflecting the reduced mechanical tension on the vessel walls. However, CAVI remained unchanged, demonstrating its independence from BP changes driven by cardiac output.

In contrast, Doxazosin administration led to a similar drop in BP, but because this drop was achieved through the relaxation of arterial smooth muscle, both baPWV and CAVI decreased significantly. This indicates that CAVI is sensitive to the functional state of the arterial wall (smooth muscle contractility) even while ignoring the mechanical effect of the blood pressure itself.

Correlation Analysis

To further validate these findings, researchers analyzed the correlation between the change in blood pressure ($\Delta$BP) and the change in stiffness metrics ($\Delta$CAVI and $\Delta$baPWV).

Figure 5: Correlation between changes in blood pressure and changes in arterial stiffness metrics (CAVI and baPWV) during Metoprolol administration.

In the Metoprolol group (Figure 5), there was no significant correlation between $\Delta$SBP/$\Delta$DBP and $\Delta$CAVI (Panels A and B), whereas $\Delta$baPWV showed a clear positive correlation with BP changes (Panels C and D). This statistical divergence confirms that CAVI successfully "subtracts" the mechanical influence of blood pressure that typically confounds PWV measurements.

Discussion and Conclusion

The study confirms that CAVI is a robust, BP-independent metric for assessing arterial stiffness. It distinguishes between the mechanical effect of pressure and the functional state of the vessel. While baPWV fluctuates with any change in BP, CAVI only changes when the intrinsic tone of the arterial smooth muscle is altered.

These findings suggest that CAVI is not merely a measure of permanent structural damage (arteriosclerosis) but also a sensitive real-time monitor of vascular smooth muscle function. This makes it a superior tool for evaluating the true state of the vasculature, particularly in patients where fluctuating blood pressure might otherwise lead to inaccurate assessments of cardiovascular risk.

Summary updated

Abstract

These results suggested that CAVI was not affected by blood pressure at the measuring time directly, but affected by the changes of contractility of smooth muscle cells.
BibTeX
@article{shirai2011contradictory,
  author = {Kohji Shirai and Mingling Song and Jun Suzuki and Takumi Kurosu and Tomokazu Oyama and Daiji Nagayama and Yoh Miyashita and Shigeo Yamamura and M Takahashi},
  title = {{Contradictory Effects of β1- and α1- Aderenergic Receptor Blockers on Cardio-Ankle Vascular Stiffness Index (CAVI)}},
  journal = {Journal of Atherosclerosis and Thrombosis},
  year = {2011},
  doi = {10.5551/jat.3582},
}
Figure